Abstracts tagged "Adalimumab"

Abstract Number: 499 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial
Robin Christensen¹, Simon Tarp¹, Daniel Furst², Lars E. Kristensen³ and Henning Bliddal⁴, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²David Geffen School of Medicine, University of California, Los Angeles, CA, ³Rheumatology, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Rheumatology, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Using combined data from the ATTEST [1] and AMPLE [2] study comparing infliximab and adalimumab with abatacept in patients with rheumatoid arthritis (RA), we…
Abstract Number: 2598 • 2012 ACR/ARHP Annual Meeting
Anti-Drug Antibodies Are Associated with Diminished Drug Levels and Treatment Failure
Miha Kosmac¹, Natasa Toplak², Gabriele Simonini³, Ilaria Pagnini⁴, Rolando Cimaz⁵, Vladka Curin Serbec¹ and Tadej Avcin⁵, ¹Research and Development Unit, Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia, ²Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital Ljubljana Slovenia, Ljubljana, Slovenia, ³Rheumatology Unit-Department of Paediatrics, A. Meyer Children's Hospital, Florence, Italy, ⁴Rheumatoloy Unit, Anna Meyer Children's Hospital, Department of Pediatrics, University of Florence, Florence, Italy, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Due to their proteinaceus character biologics can often induce an unwanted immune response that results in the formation of anti-drug antibodies in patients receiving…
Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Chad Pool¹, Gopi Shankar², Allen Schantz², George Gunn², Rebecca Bolce³, Marjatta Leirisalo-Repo⁴, Jim Wang¹, John A. Goldman⁵, Raphael J. DeHoratius⁶, Roy Fleischmann⁷ and Dennis Decktor⁶, ¹Janssen Services, LLC, Horsham, PA, ²Janssen R&D, LLC, PA, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Medical Quarters #293, Atlanta, GA, ⁶Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁷Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…
Abstract Number: 5 • 2012 ACR/ARHP Annual Meeting
Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure
Bohdan P. Harvey¹ and Zehra Kaymakcalan², ¹Biologics, Abbott Laboratories, Worcester, MA, ²Biologics, Abbott, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …
Abstract Number: 2466 • 2012 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: The OTIS Autoimmune Diseases in Pregnancy Project
Christina D. Chambers¹, Diana L. Johnson², Yunjun Luo¹, Janina L. Jimenez¹, Nicole Mirrasoul¹, Elizabeth Salas¹, Kenneth Lyons Jones² and OTIS Research Group³, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Pediatrics, La Jolla
Background/Purpose: The fully human, anti-tumor necrosis factor monoclonal antibody, adalimumab (ADA), is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile…
Abstract Number: 1242 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis
Mike Nurmohamed¹, Yanjun Bao², James Signorovitch³, Parvez M. Mulani⁴ and Daniel Furst⁵, ¹VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands, ²AbbVie, North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Abbott Laboratories, Abbott Park, IL, ⁵Div of Rheumatology, UCLA Medical School, Los Angeles, CA
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the…
Abstract Number: 2463 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis
Josh J. Carlson¹, Sarika Ogale², Fred Dejonckheere³ and Sean Sullivan⁴, ¹Pharmacy, University of Washington, Seattle, WA, ²Genentech, South San Francisco, CA, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: The ADACTA trial found that biologic naïve patients with severe active RA who are methotrexate (MTX) intolerant or in whom continued MTX treatment is…
Abstract Number: 1140 • 2012 ACR/ARHP Annual Meeting
Response to Adalimumab in 40 Patients with refractory juvenile Idiopathic Arthritis-Associated Uveitis. A Multicenter Study
Vanesa Calvo-Río¹, Ricardo Blanco², Manuel Díaz-Llopis³, David Salom⁴, Carmen García-Vicuña⁵, Miguel Cordero-Coma⁶, Norberto Ortego⁷, Marta Suarez-de-Figueroa⁸, J. Carlos Fernandez-Cid⁹, A. Fonollosa Calduch¹⁰, Ángel M. García-Aparicio¹¹, Jose M. Benítez-del-Castillo¹², Jose L. Olea¹³, Javier Loricera¹⁴ and Miguel Angel González-Gay¹⁵, ¹Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Universitario La Fe de Valencia, Valencia, ⁴Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, ⁵Hospital Sant Joan de Déu, Barcelona, Barcelona, ⁶Departament of Ophthalmology, Hospital de León, León, Spain, ⁷Hospital San Cecilio. Granada, Granada, Spain, ⁸Department of Ophthalmology, Hospital Ramon y Cajal, Madrid, Spain, ⁹Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ¹⁰Ophthalmology, Hospital de Cruces, Barakaldo, Spain, ¹¹Hospital Virgen Salud, Toledo, Toledo, ¹²Departament of Ophthalmology, Hospital Clínico San Carlos, Madrid, ¹³Departament of Ophthalmology, Hospital Son Dureta, Palma de Mallorca, Spain, ¹⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ¹⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain
Background/Purpose: To assess the efficacy and safety of treatment with adalimumab therapy in patients with refractory Juvenile Idiopathic Arthritis (JIA)-associated uveitis. Methods: Multicenter study on…
Abstract Number: 2227 • 2012 ACR/ARHP Annual Meeting
Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO
Bjorn Gudbjornsson¹ and Niels Steen Krogh², ¹Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ²ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and…
Abstract Number: 1015 • 2012 ACR/ARHP Annual Meeting
Analysis of Integrated Radiographic Data for Two Long-Term, Open-Label Extension Studies of Adalimumab
Désirée van der Heijde¹, Robert Landewé², Edward Keystone³, Ferdinand C. Breedveld⁴, Shufang Liu⁵ and Neelufar Mozaffarian⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Int Med/Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ³University of Toronto, Professor of Medicine, Toronto, ON, Canada, ⁴Dept of Rheumatology C1R, Leiden University Medical Center, Leiden, Netherlands, ⁵Immunology Development, Abbott, Abbott Park, IL, ⁶Abbott, Abbott Park, IL
Background/Purpose: The assessment of radiographic data from long-term studies in patients (pts) with rheumatoid arthritis (RA) poses a significant challenge, given the potential involvement of…
Abstract Number: 2234 • 2012 ACR/ARHP Annual Meeting
US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab
Frank Zhang¹, Stan Li² and Jeffrey R. Curtis³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²Pricing and Market Access, Celgene Corporation, Warren, NJ, ³Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Etanercept (ETN) and Adalimumab (ADA) are commonly used biologic disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) patients (pts). However, little is known about…
Abstract Number: 995 • 2012 ACR/ARHP Annual Meeting
Genetic Effects of HLA-DRB1, IL4R, and FcγRIIb On Long-Term Treatment Responses in Patients with Early Rheumatoid Arthritis: 78-Week Results of a Phase 4 Study
Alla Skapenko¹, Josef S. Smolen², Arthur Kavanaugh³, Vipin Arora⁴, Hartmut Kupper⁵ and Hendrik Schulze-Koops⁶, ¹Division of Rheumatology and Clinical Immunology, Med. Poliklinik,, University of Munich, Munich, Germany, ²Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ³UCSD School of Medicine, La Jolla, CA, ⁴Health Outcomes Research, Abbott, Abbott Park, IL, ⁵Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁶University of Munich, Munich, Germany
Background/Purpose: Previous analyses suggested that the HLA-DRB1 shared epitope (SE), and the IL4R V50I and the FcγRIIb I232T single nucleotide polymorphisms (SNPs) affected response to…
Abstract Number: 2217 • 2012 ACR/ARHP Annual Meeting
Even After Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients
Frank Behrens¹, Michaela Koehm¹, Diamant Thaci², Brigitte Krummel-Lorenz³, Gerd Greger⁴, Bianca Wittig⁴ and Harald Burkhardt⁵, ¹CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, ²Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, ³CIRI/Endokrinologikum, Frankfurt/Main, Germany, ⁴Abbott GmbH & Co KG, Wiesbaden, Germany, ⁵CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Frankfurt/Main, Germany
Background/Purpose: For the treatment of patients with psoriatic arthritis (PsA) only antiTNF biologics are licensed. Therefore, failures to anti-TNF are often switched to a different…
Abstract Number: 775 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
Roy Fleischmann¹, Ronald F. van Vollenhoven², Josef S. Smolen³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Hartmut Kupper⁷ and Arthur Kavanaugh⁸, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Karolinska Institute, Stockholm, Sweden, ³Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁸UCSD School of Medicine, La Jolla, CA
Background/Purpose: In rheumatoid arthritis (RA), anti-TNF therapy is considered following 3-6 months of failed methotrexate (MTX) treatment. Some patients (pts), particularly those with many risk…
Abstract Number: 2173 • 2012 ACR/ARHP Annual Meeting
Pharmacoeconomic Evaluation of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis
Navarro Sarabia F¹, Francisco J. Blanco V², Álvaro Gracia JM³, JA García Meijide⁴ and Jl Poveda⁵, ¹Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, ²Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ³Rheumatology Service, H. Universitario La Princesa, Madrid, SC, Spain, ⁴Rheumatologist Service, Hospital Ntra. Sra. La Esperanza, Santiago de Compostela, Spain, ⁵Pharmacy Service, Hospital Universitario La Fe, Valencia, Spain
Background/Purpose: ADACTA trial (Gabay C et al EULAR June 2012) showed that tocilizumab (TCZ) monotherapy was superior to adalimumab (ADA) monotherapy in reducing signs and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].